Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash & Current Investments (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Cash & Current Investments for 6 consecutive years, with $25.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Current Investments fell 58.19% year-over-year to $25.5 million, compared with a TTM value of $25.5 million through Sep 2025, down 58.19%, and an annual FY2024 reading of $53.1 million, down 48.54% over the prior year.
  • Cash & Current Investments was $25.5 million for Q3 2025 at Ovid Therapeutics, down from $38.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $233.1 million in Q1 2021 and bottomed at $25.5 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $116.1 million, with a median of $103.1 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments skyrocketed 414.29% in 2021, then tumbled 58.19% in 2025.
  • Year by year, Cash & Current Investments stood at $187.8 million in 2021, then crashed by 32.83% to $126.1 million in 2022, then dropped by 18.25% to $103.1 million in 2023, then tumbled by 48.54% to $53.1 million in 2024, then tumbled by 52.0% to $25.5 million in 2025.
  • Business Quant data shows Cash & Current Investments for OVID at $25.5 million in Q3 2025, $38.3 million in Q2 2025, and $40.8 million in Q1 2025.